The Impact of Cardiac Resynchronization Therapy on the Frequency of Ventricular Arrhythmias

Adam S Budzikowski¹*, Ofek Hai², Andrew Beck¹, Alexander Khodak¹ and Cristina A. Mitre¹

¹Division of Cardiovascular Medicine-EP Section, SUNY Downstate, USA
²Division of Cardiology, Nassau University Medical Center, East Meadow, USA

Background: Cardiac resynchronization therapy (CRT) has a proven role in improving mortality in patients with heart failure and ventricular dyssynchrony. However, the effects of biventricular pacing (CRT) on ventricular arrhythmia susceptibility have not been definitively established, and data regarding the risk of ventricular arrhythmias (VA) with CRT has been limited and conflicting. The aim of this study was to compare the burden of VA in the short term before and after an upgrade to a cardiac resynchronization device in order to avoid the long term effects of myocardial remodeling.

Methods: We analyzed 44 consecutive patients with severe LV systolic dysfunction who underwent an upgrade from a single chamber defibrillator to biventricular defibrillator due to worsening heart failure status.

Results: CRT was associated with a decrease in VA in patients with high arrhythmic burden, in women and in patients older than 65.

Conclusion: In this study we provide convincing evidence that in patients with identical electrophysiologic substrate, biventricular pacing alone is associated with a decrease in VA burden.

Keywords: Cardiac resynchronization therapy; Ventricular arrhythmias; Myocardial remodeling

Abbreviations: ATP: Antitachycardia Pacing; CRT: Cardiac Resynchronization Therapy; ICD: Implantable Cardioverter Defibrillator; LV: Left Ventricular; LVEDD: Left Ventricular End Diastolic Diameter; NYHA: New York Heart Association; VA: Ventricular Arrhythmia; VT: Ventricular Tachycardia

Introduction

Cardiac Resynchronization Therapy (CRT) has emerged as a highly effective treatment modality for patients with systolic heart failure and prolonged QRS duration. Meta-analysis has shown that CRT, in addition to optimal medical therapy, reduces mortality in patients with heart failure [1], improves symptoms, exercise tolerance and decreases hospital admissions [2]. However, the effect of CRT on arrhythmia susceptibility has not been definitively established and data regarding the risk of ventricular arrhythmias (VA) with CRT has been limited and conflicting. Case reports have provided anecdotal evidence of CRT precipitating ventricular tachycardia [3,4]; moreover the presence of scarred myocardium has been associated with an increased risk of arrhythmia in CRT [5,6]. Multiple mechanisms have been proposed for this phenomenon. Epicardial pacing results in a reversal of the normal physiologic myocardial activation sequence, which prolongs the QT interval and produces a substrate and the trigger for reentrant arrhythmias in both canine and human subjects [5,7]. The CRT non-responders also experience an increase in ventricular arrhythmia burden [8]. On the other hand, CRT has been shown to reduce the incidence VA, likely by virtue of the reverse remodeling of the myocardium [9,10].

Therefore, the aim of this study was to ascertain the true electrophysiologic effects of CRT on the burden of the VA by comparing frequency of the VA in the short term before and after an upgrade to a cardiac resynchronization therapy in order to avoid the long-term effects of myocardial remodeling.

Methods

We analyzed retrospectively 44-consecutive patients with severe left ventricular (LV) systolic dysfunction who underwent an upgrade from a single chamber defibrillator to biventricular defibrillator in our institution due to worsening heart failure status in the presence of left bundle branch block and with a QRS duration greater than 120 ms. Patients who were implanted for secondary prevention of sudden cardiac death and patients with hereditary arrhythmias were excluded from this analysis. Nearly all left ventricular leads were implanted percutaneously. Lead position was identified through the review of fluoroscopy in left anterior and right anterior oblique projections. Lead position was also identified through the review of posterior-anterior and lateral chest radiograms by an independent reviewer.

Baseline demographic variables, indices of LV size and function, symptomatic status, and pharmacologic therapy were collected from...
retrospective chart review. Arrhythmia frequency and characteristics 6 months before and 6 months after an upgrade were determined by the review of routine and unscheduled device interrogation data. Echocardiographic measurements were performed mostly with Phillips Epic ultrasound system. All measurements were done in accordance with ASE guidelines [11].

Classification of events:
All episodes were reviewed by 2 independent electrophysiologists. If disagreement was found, the event was classified by a consensus. Ventricular tachycardia was identified by a rate greater than 170 bpm, regularity of rate and the following: evidence of V-A dissociation and a local electrogram morphology different from baseline. If 1:1 A:V relationship was present, V-V changes had to drive A-A changes. Ventricular fibrillation was identified by rate greater than 210 bpm and disorganized ventricular electrograms. Only the six months preceding and following an upgrade were studied. In that time frame, all ventricular events, which included those that were non-sustained or that required either ATP or shock therapy, were used for analysis.

Statistical analysis
Arrhythmic burden was measured as the sum of ventricular episodes. All data were checked for normalcy. Related samples: Wilcoxon signed rank test was used to compare the differences in cumulative ventricular events in pre-CRT vs. post CRT groups. The Kruskal-Wallis test was used to investigate whether LV lead positioning or polarity was associated with increased or decreased frequency of ventricular arrhythmias. SPSS software was used for statistical analysis. A p-value of <0.05 was considered significant. The study protocol was reviewed and approved by the SUNY Downstate Institutional Review Board.

Results
Baseline characteristics
Demographic and clinical characteristics of the patient cohort are noted in Table 1. Over two-thirds of the patients were males older than 65 years of age. Half of the patients had an ischemic etiology of heart failure and most were in NYHA functional class III at the time of the upgrade. The mean ejection fraction ± SD was 24.6 ± 8.9 and the mean QRS duration was 146.1 ± 25.4 ms. None of the patients had AV nodal conduction disease. The distribution of LV lead location and pacing configurations are shown in Table 2. The post-CRT upgrade relation of QRS duration, echocardiographic and device parameters are shown in Table 3.

| Clinical and Demographic Features | Number of patients=25 (Mean ± SD or n (%)) |
|-----------------------------------|---------------------------------------------|
| Age (years)                       | 64.9 ± 11.4                                  |
| Gender                            |                                             |
| Male                              | 20 (80%)                                     |
| Female                            | 5 (20%)                                      |
| Race                              |                                             |
| White                             | 1 (4%)                                       |

| Etiology                          |                                             |
|-----------------------------------|---------------------------------------------|
| Ischemic                          | 17 (68%)                                     |
| Non-ischemic                      | 8 (32%)                                      |

| NYHA class                        |                                             |
|-----------------------------------|---------------------------------------------|
| I                                 | 0                                           |
| II                                | 2 (8%)                                      |
| III                               | 21 (84%)                                    |
| IV                                | 2 (8%)                                      |

| QRS duration prior to implant (ms) | 146.3 ± 19.5 |
|-----------------------------------|--------------|
| LVEF prior to Implant (%)         | 22.5 ± 7.2   |
| LV pacing (%)                     | 98.2 ± 2.2   |

| Medications                       |                                             |
|-----------------------------------|---------------------------------------------|
| Beta blockers                     | 24 (96%)                                    |
| ACEI/ARBS                         | 24 (96%)                                    |
| Amiodarone                        | 2 (8%)                                      |

| QRS duration (ms)                 | 138.0 ± 11.9                                |
|-----------------------------------|---------------------------------------------|
| QRS narrowing                     | 168.1 ± 20.4                                |
| P                                 | 0.001                                       |
| LVEF (%)                          | 31.4 ± 16.2                                 |
| LVEDD (cm)                        | 6.8 ± 1.0                                   |
| LVESD (cm)                        | 5.8 ± 1.4                                   |
| LV sensing (mV)                   | 10.0 ± 6                                    |
|                                  | 14.1 ± 7.5                                  |
|                                  | 0.08                                        |

Table 1: Clinical and demographic characteristics of the cohort

Table 2: CRT LV Lead placement and configuration

Table 3: Post CRT upgrade relation of QRS duration, echocardiographic and device parameters
Ventricular events

The mean (SD) cumulative ventricular events in the entire cohort before and after CRT implantation were 7.4 ± 21.6 and 5.6 ± 11.6 episodes per patient p=0.52. When individual change in the number of events (ΔVA) in each patient was analyzed in relation to the frequency of pre-upgrade events, it was shown that patients with the highest number of pre-upgrade events had the biggest reduction in VT events (Figure 1) p ≤ 0.01. Post CRT upgrade females, compared to males, had significant reduction in ΔVA -5.0 ± 15.2 vs. -0.56 ± 25.1, respectively, p=0.043. Similarly, older patients >65 had greater reduction in events that those under 65 -4.24 ± 0.54 vs. -3.0 ± 0.71, respectively, p=0.029. Neither the LV lead position, the pacing polarity, baseline LV size, heart failure class, nor voltage sensed by the LV lead had a significant impact on the ΔVA in the short term after CRT implantation (p=ns, all) (Table 2).

In conclusion, in this study we provide initial evidence that in patients with similar electrophysiological substrate, CRT reduces VA burden, particularly in patients with preexisting VA, women and those older than 65.

Discussion

In this study, we have demonstrated that patients with high burden of VA, those that are older than 65 and females experience reduction in VA as a result of resynchronization therapy. CRT has emerged as a vital method for improving overall outcomes in the management of patients with mild to severe heart failure and ventricular dysynchrony, as CRT has been shown to improve morbidity and mortality in these patients [1,2,12]. A decrease [9,10] or no change [13] in the burden of ventricular arrhythmias has been reported with cardiac resynchronization, but these studies looked at long-term changes and are affected by the reverse remodeling of the myocardium. An improvement in the burden of the VA appears to be most pronounced in CRT responders, which suggests that reverse remodeling may have a pivotal role in this process [8,10]. Therefore, the pure electrophysiologic effect of CRT therapy can only be reliably assessed before significant reverse remodeling occurs [13]. Our study suggests that the reported decrease in VA burden occurs early after the initiation of CRT and is maintained in the long term [10]. To our knowledge, this is the first study that shows that CRT benefits the elderly and those with a preexisting VA burden.

At the very fundamental level, the presence of myocardial scar and viable tissue creates milieu for ventricular arrhythmia by allowing non-homogenous spread of depolarization wavefront and the creation of reentry [6,14-17]. At the same time, one could construe that under correct circumstances colliding wavefronts of depolarization resulting from CRT may also extinguish the reentry. Diminishing of intraventricular conduction delay, and prevention of pause-dependent tachyarrhythmias, as seen with CRT, may contribute to this phenomenon as well [18]. All these effects could be dependent on LV location [19] and proximity to the scar [5]. Neither the LV lead position, the pacing polarity, baseline LV size, heart failure class, nor voltage sensed by the LV lead had a significant impact on the ΔVA in the short term after CRT implantation (p=ns, all) (Table 2).

![Figure 1: Cumulative burden of ventricular events pre vs. post CRT upgrade (3.1 ± 14.4 and 2.1 ± 5.2; p=0.53 Wilcoxon signed rank test).](image)

We acknowledge that our study is observational in nature and is hindered by small sample size. Also, our patients are predominantly male and of African American ancestry, which can potentially affect the applicability of our study results to the general population.

Conclusions

In conclusion, in this study we provide initial evidence that in patients with similar electrophysiological substrate, CRT reduces VA burden, particularly in patients with preexisting VA, women and those older than 65.

References

1. Wells G, Parkash R, Healey JS, Talajic M, Arnold JM, et al. (2011) Cardiac resynchronization therapy: a meta-analysis of randomized controlled trials. Cmaj 183: 421-429.
2. Leclercq C, Cazeau S, Lellouche D, Fossati F, Anselme F, et al. (2007) Upgrading from single chamber right ventricular to biventricular pacing in permanently paced patients with worsening heart failure: The RD-CHF Study. Pacing Clin Electrophysiol Suppl 1: S23-S30.
3. Kantharia BK, Patel JA, Nagra BS, Ledley GS (2006) Electrical storm of monomorphic ventricular tachycardia after a cardiac-resynchronization-therapy-defibrillator upgrade. Europace 8: 625-628.
4. Yamada T, Tabereaux PB, McElderry HT, Doppalapudi H, Epstein AE, et al. (2010) Successful catheter ablation of epicardial ventricular

Citation: Budzikowski AS, Hai O, Beck A, Khodak A, Mitre CA (2018) The Impact of Cardiac Resynchronization Therapy on the Frequency of Ventricular Arrhythmias. J Clin Exp Cardiolog 9: 587. doi:10.4172/2155-9880.1000587
tachycardia worsened by cardiac resynchronization therapy. Europace 12: 437-440.

5. Zizek D, Cvijic M, Lezaic L, Salobir BG, Zupan I (2013) Impact of myocardial viability assessed by myocardial perfusion imaging on ventricular tachyarrhythmias in cardiac resynchronization therapy. J Nucl Cardiol 20: 1049-1059.

6. Fernandez-Armenta J, Berruezo A, Mont L, Sitges M, Andreu D, et al. (2012) Use of myocardial scar characterization to predict ventricular arrhythmia in cardiac resynchronization therapy. Europace 14: 1578-1586.

7. Fish JM, Brugada J, Antzelevitch C (2005) Potential proarrhythmic effects of biventricular pacing. J Am Coll Cardiol 46: 2340-2347.

8. Thijssen J, Borleffs CJ, Delgado V, van Rees JB, Mooyaart EA, et al. (2011) Implantable cardioverter-defibrillator patients who are upgraded and respond to cardiac resynchronization therapy have less ventricular arrhythmias compared with nonresponders. J Am Coll Cardiol 58: 2282-2289.

9. Ermis C, Seutter R, Zhu AX, Benditt LC, VanHeel L, et al. (2005) Impact of upgrade to cardiac resynchronization therapy on ventricular arrhythmia frequency in patients with implantable cardioverter-defibrillators. J Am Coll Cardiol 46: 2258-2263.

10. Di Biase L, Gasparini M, Lunati M, Santini M, Landolina M, et al. (2008) Antiarrhythmic effect of reverse ventricular remodeling induced by cardiac resynchronization therapy: the InOync ICD (Implantable Cardioverter-Defibrillator) Italian Registry. J Am Coll Cardiol 52: 1442-1449.

11. Lang RM, Badano LP, Mor-Avi V, Aifalos J, Armstrong A, et al. (2015) Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 16: 233-270.

12. Moss AJ, Hall WJ, Cannon DS, Klein H, Brown MW, et al. (2009) Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med 361: 1329-1338.

13. Lin G, Rea RF, Hammill SC, Hayes DL, Brady PA (2008) Effect of cardiac resynchronisation therapy on occurrence of ventricular arrhythmia in patients with implantable cardioverter defibrillators undergoing upgrade to cardiac resynchronisation therapy devices. Heart 94: 186-190.

14. Nazarian S, Bluemke DA, Lardo AC, Zviman MM, Watkins SP, et al. (2005) Magnetic resonance assessment of the substrate for inducible ventricular tachycardia in nonischemic cardiomyopathy. Circulation 112: 2821-2825.

15. Bello D, Fieno DS, Kim RJ, Pereles FS, Passman R, et al. (2005) Infarct morphology identifies patients with substrate for sustained ventricular tachycardia. J Am Coll Cardiol 45: 1104-1108.

16. Schmidt A, Azevedo CF, Cheng A, Gupta SN, Bluemke DA, et al. (2007) Infarct tissue heterogeneity by magnetic resonance imaging identifies enhanced cardiac arrhythmia susceptibility in patients with left ventricular dysfunction. Circulation 115: 2006-2014.

17. Varma N (2015) Left ventricular electrical activation during right ventricular pacing in heart failure patients with LBBB: visualization by electrocardiographic imaging and implications for cardiac resynchronization therapy. J Electrocardiol 48: 53-61.

18. Bilchick KC, Helm RH, Kass DA (2007) Physiology of biventricular pacing. Curr Cardiol Rep 9: 358-365.

19. Kutyifa V, Zareba W, McNitt S, Singh J, Hall WI, et al. (2013) Left ventricular lead location and the risk of ventricular arrhythmias in the MADIT-CRT trial. Eur Heart J 34: 184-190.

20. Leyva F, Foley PW, Challil S, Irwin N, Smith RE (2011) Female gender is associated with a better outcome after cardiac resynchronization therapy. Pacing Clin Electrophysiol 34: 82-88.

21. Cheng YJ, Zhang J, Li WJ, Lin XX, Zeng WT, et al. (2014) More favorable response to cardiac resynchronization therapy in women than in men. Circ Arrhythm Electrophysiol 7: 807-815.

22. Zabarowska S, Gadler F, Braunschweig F, Stahlberg M, Hornstein I, et al. (2012) Women have better long-term prognosis than men after cardiac resynchronization therapy. Europace 14: 1148-1155.

23. Schuchert A, Muto C, Maounis T, Frank R, Ella RO, et al. (2013) Gender-related safety and efficacy of cardiac resynchronization therapy. Clin Cardiol 36: 683-690.

24. Risum N, Williams ES, Khouri MG, Jackson KP, Olsen NT, et al. (2013) Mechanical dyssynchrony evaluated by tissue Doppler cross-correlation analysis is associated with long-term survival in patients after cardiac resynchronization therapy. Eur Heart J 34: 48-56.

25. Frigerio M, Lunati M, Pasqualucci D, Vargiu S, Foli G, et al. (2014) Left ventricular ejection fraction crossing 35% after one year of cardiac resynchronization therapy predicts long term survival and freedom from sudden cardiac death: single center observational experience. Int J Cardiol 172: 64-71.

26. Huang DT, Sesselberg HW, McNitt S, Noyes K, Andrews ML, et al. (2007) Improved survival associated with prophylactic implantable defibrillators in elderly patients with prior myocardial infarction and depressed ventricular function: a MADIT-II substudy. J Cardiovasc Electrophysiol 18: 833-838.

27. Daubert JP, Sesselberg HW, Huang DT (2006) Implantable cardioverter-defibrillators for primary prevention: how do the data pertain to the aged? Am J Geriatr Cardiol 15: 88-92.

28. Thomas S, Moss AJ, Zareba W, McNitt S, Barsheeshet A, et al. (2016) Cardiac Resynchronization in Different Age Groups: A MADIT-CRT Long-Term Follow-Up Substudy. J Card Fail 22: 143-149.

29. Heidenreich PA, Tsiav A, Bao H, Curtis J, Goldstein M, et al. (2015) Does Age Influence Cardiac Resynchronization Therapy Use and Outcome? JACC Heart Fail 3: 497-504.

30. Elancheney M, Moss AJ, McNitt S, Akbas M, Polonsky S, et al. (2013) Effectiveness of cardiac resynchronization therapy with defibrillator in at-risk black and white cardiac patients. Ann Noninvasive Electrocardiol 18: 140-148.

31. Russo AM, Hafley GE, Lee KL, Stamato NJ, Lehmann MH, et al. (2003) Racial differences in outcome in the Multicenter UnSustained Tachycardia Trial (MUSTT): a comparison of whites versus blacks. Circulation 108: 67-72.

32. Mitchell JE, Hellkamp AS, Mark DB, Anderson J, Poole JE, et al. (2008) Outcome in African Americans and other minorities in the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Am Heart J 155: 501-506.

33. Vorobiof G, Goldenberg J, Moss AJ, Zareba W, McNitt S (2006) Effectiveness of the implantable cardioverter defibrillator in blacks versus whites (from MADIT-II). Am J Cardiol 98: 1383-1386.